Alexion beats Street, raises guidance

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) reported 3Q09 diluted GAAP EPS of $0.29, beating by $0.08 the Street's estimate of $0.21 and up from $0.23 in 3Q08. Third quarter sales of Soliris eculizumab for paroxysmal nocturnal hemoglobinuria (PNH) were $102.6 million, up 34% from $76.5 million in 3Q08. The Street was expecting sales of $98.3 million. ...